에 대한 최신 뉴스 Simulations Plus (NASDAQ:SLP) 주식

Simulations Plus

Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.

Earnings

News

Small Cap

Pre-Market Outlook

Markets

Trading Ideas

LEVI

주식선물이 이번 목요일 아침 미국에서 상승하면서, 오늘 투자자들의 주목을 끌 수 있는 몇 가지 주식은 다음과 같습니다.

월스트리트는 Conagra Brands, Inc.(NYSE:CAG)의 오프닝벨 전에 1주당 65센트의 분기 실적과 301억달러의 매출을 발표할 것으로 예상하고 있습니다. 이는벤징가 프로의 데이터에 따른 것입니다. Conagra 주식은 매출 후 시간에 1.2% 상승하여

리바이스, 콘아그라 브랜즈와 목요일로 향하는 3종목의 주식

Simulations Plus Inc

Smooth Love Potion - United States Dollar

SIMPLEX HLDGS INC by SIMPLEX HLDGS INC.

Stephens &amp; Co. analyst Jeff Garro initiates coverage on Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) with a Overweight rating and announces Price Target of $39.

Price Target

Initiation

Analyst Ratings

Stephens & Co. Initiates Coverage On Simulations Plus with Overweight Rating, Announces Price Target of $39

Simulations Plus And University Of Connecticut Receive FDA Grant To Expand Mechanistic Modeling Approaches For Long-Acting Injectables Using PBPK Models To Improve Bioequivalence Predictions

William Blair analyst Max Smock reiterates Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) with a Outperform.

Reiteration

William Blair Reiterates Outperform on Simulations Plus

Collaboration goal to develop alternative methods to assess clinical performance of product variants under different conditions

Biotech

General

Simulations Plus And Partners Wins FDA Grant To Validate In Vitro-In Vivo Extrapolation Methods For Complex Formulations

BTIG analyst David Larsen maintains Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) with a Buy and lowers the price target from $60 to $50.

BTIG Maintains Buy on Simulations Plus, Lowers Price Target to $50

WIIM

Simulations Plus shares are trading lower after the company reported worse-than-expected Q4 revenue results.

Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.03 by 100 percent. This is a 66.67 percent decrease over earnings of $0.18 per share from the same period last year. The company reported quarterly sales of $18.70 million which missed the analyst consensus estimate of $19.74 million by 5.27 percent. This is a 19.87 percent increase over sales of $15.60 million the same period last year.

Earnings Beats

Earnings Misses

Simulations Plus Q4 Adj $0.06 Beats $0.03 Estimate, Sales $18.70M Miss $19.74M Estimate

Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) is looking for FY2025 Adj EPS of $1.07-1.20. sees sales of $90.000 million-93.000 million vs $91.75 million estimate.

Guidance

Simulations Plus Sees FY2025 Adj EPS $1.07-1.20; Sees Sales $90.000M-93.000M vs $91.75M Est.

Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) will release its quarterly earnings report on Wednesday, 2024-10-23. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Simulations Plus to report an earnings per share (EPS) of $0.03.
Simulations Plus bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.04, leading to a 14.87% drop in the share price on the subsequent day.
Here's a look at Simulations Plus's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.15</td>
<td>0.19</td>
<td>0.1</td>
<td>0.18</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.19</td>
<td>0.20</td>
<td>0.1</td>
<td>0.18</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-15.0%</td>
<td>24.0%</td>
<td>-5.0%</td>
<td>-15.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1729623716_0.png" alt="eps graph" />
<h3>Market Performance of Simulations Plus's Stock</h3>
Shares of Simulations Plus were trading at $34.28 as of October 21. Over the last 52-week period, shares are down 12.04%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<h3>Insights Shared by Analysts on Simulations Plus</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Simulations Plus.
A total of 1 analyst ratings have been received for Simulations Plus, with the consensus rating being Outperform. The average one-year price target stands at $47.0, suggesting a potential 37.11% upside.
<h3>Comparing Ratings with Competitors</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of Definitive Healthcare, Health Catalyst and HealthStream, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<ul>
<li>The consensus among analysts is an Neutral trajectory for Definitive Healthcare, with an average 1-year price target of $5.61, indicating a potential 83.63% downside.</li>
<li>The consensus among analysts is an Outperform trajectory for Health Catalyst, with an average 1-year price target of $13.12, indicating a potential 61.73% downside.</li>
<li>Analysts currently favor an Neutral trajectory for HealthStream, with an average 1-year price target of $28.0, suggesting a potential 18.32% downside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Definitive Healthcare, Health Catalyst and HealthStream, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simulations Plus</td>
<td>Outperform</td>
<td>14.23%</td>
<td>$13.26M</td>
<td>1.75%</td>
</tr>
<tr>
<td>Definitive Healthcare</td>
<td>Neutral</td>
<td>4.56%</td>
<td>$50.45M</td>
<td>-28.39%</td>
</tr>
<tr>
<td>Health Catalyst</td>
<td>Outperform</td>
<td>3.67%</td>
<td>$35.84M</td>
<td>-3.78%</td>
</tr>
<tr>
<td>HealthStream</td>
<td>Neutral</td>
<td>3.41%</td>
<td>$47.82M</td>
<td>1.20%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Simulations Plus ranks first in revenue growth among its peers. It also leads in gross profit margin. However, it has the lowest return on equity.
<h3>Discovering Simulations Plus: A Closer Look</h3>
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. It generates maximum revenue from the software segment.
<h3>Simulations Plus: A Financial Overview</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Simulations Plus showcased positive performance, achieving a revenue growth rate of 14.23% as of 31 May, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Simulations Plus's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 16.92%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 1.75%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Simulations Plus's ROA excels beyond industry benchmarks, reaching 1.62%. This signifies efficient management of assets and strong financial health.
Debt Management: Simulations Plus's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/SLP/earnings">To track all earnings releases for Simulations Plus visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What to Expect from Simulations Plus's Earnings

A substantial insider move unfolded on October 21, as DiBella, Business Unit President at Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>), reported the acquisition of stock options for 7,500 shares in an SEC filing.
What Happened: Uncovered in a Form 4 filing on Monday with the <a href="https://www.sec.gov/Archives/edgar/data/0001023459/000102345924000119//Archives/edgar/data/1023459/000102345924000119/0001023459-24-000119-index.htm">U.S. Securities and Exchange Commission</a>, DiBella, Business Unit President at Simulations Plus, executed an insider options move. This move consisted of acquiring stock options for 7,500 shares of SLP, granting DiBella the right to purchase the company's stock at an exercise price of $33.29 per share.
Simulations Plus shares are currently trading down by 0.82%, with a current price of $34.0 as of Tuesday morning. This brings the total value of DiBella's 7,500 shares to $5,325.
<h3>Delving into Simulations Plus's Background</h3>
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. It generates maximum revenue from the software segment.
<h3>Understanding the Numbers: Simulations Plus's Finances</h3>
Revenue Growth: Simulations Plus displayed positive results in 3 months. As of 31 May, 2024, the company achieved a solid revenue growth rate of approximately 14.23%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Profitability Metrics:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 71.49%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Simulations Plus's EPS reflects a decline, falling below the industry average with a current EPS of 0.16.
</li>
</ul>
Debt Management: Simulations Plus's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
Financial Valuation Breakdown:
<ul>
<li>
Price to Earnings (P/E) Ratio: Simulations Plus's current Price to Earnings (P/E) ratio of 71.42 is higher than the industry average, indicating that the stock may be overvalued according to market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 10.4 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): A high EV/EBITDA ratio of 39.26 positions the company as being more valued compared to industry benchmarks.
</li>
</ul>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
Insightful as they may be, insider transactions should be considered alongside a thorough examination of other investment criteria.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>The Insider's Guide to Important Transaction Codes</h3>
When it comes to transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001023459">Check Out The Full List Of Simulations Plus's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

In A Strategic Move, John Anthony DiBella Acquires Simulations Plus Stock Options: Enhancing Value

A notable acquisition unfolded on October 21, as DiBella, Business Unit President at Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>), reported the acquisition of stock options for 7,500 shares in an SEC filing.
What Happened: Revealed in a Form 4 filing on Monday with the <a href="https://www.sec.gov/Archives/edgar/data/0001023459/000102345924000119//Archives/edgar/data/1023459/000102345924000119/0001023459-24-000119-index.htm">U.S. Securities and Exchange Commission</a>, DiBella, Business Unit President at Simulations Plus, strategically acquired stock options for 7,500 shares of SLP. These options empower DiBella to buy the company's stock at a favorable exercise price of $33.29 per share.
The latest update on Tuesday morning shows Simulations Plus shares down by 0.82%, trading at $34.0. At this price, DiBella's 7,500 shares are worth $5,325.
<h3>All You Need to Know About Simulations Plus</h3>
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. It generates maximum revenue from the software segment.
<h3>Financial Insights: Simulations Plus</h3>
Revenue Growth: Over the 3 months period, Simulations Plus showcased positive performance, achieving a revenue growth rate of 14.23% as of 31 May, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Exploring Profitability:
<ul>
<li>
Gross Margin: With a low gross margin of 71.49%, the company exhibits below-average profitability, signaling potential struggles in cost efficiency compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Simulations Plus's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 0.16.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.01, Simulations Plus adopts a prudent financial strategy, indicating a balanced approach to debt management.
Navigating Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a higher-than-average P/E ratio of 71.42, Simulations Plus's stock is perceived as being overvalued in the market.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 10.4, Simulations Plus's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): A high EV/EBITDA ratio of 39.26 reflects market recognition of Simulations Plus's value, positioning it as more highly valued compared to industry peers.
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Unmasking the Significance of Insider Transactions</h3>
While insider transactions should not be the sole basis for making investment decisions, they can play a significant role in an investor's decision-making process.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Exploring Key Transaction Codes</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001023459">Check Out The Full List Of Simulations Plus's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

John Anthony DiBella Expands Holdings With Simulations Plus Stock Options

A notable acquisition unfolded on October 21, as Szot, Chief Revenue Officer at Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>), reported the acquisition of stock options for 7,500 shares in an SEC filing.
What Happened: In a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001023459/000102345924000121//Archives/edgar/data/1023459/000102345924000121/0001023459-24-000121-index.htm">U.S. Securities and Exchange Commission</a> on Monday, Szot, Chief Revenue Officer at Simulations Plus, acquired stock options for 7,500 shares of SLP. These options provide Szot with the right to purchase the company's stock at $33.29 per share.
Currently, Simulations Plus shares are trading down 0.82%, priced at $34.0 during Tuesday's morning. This values Szot's 7,500 shares at $5,325.
<h3>Unveiling the Story Behind Simulations Plus</h3>
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. It generates maximum revenue from the software segment.
<h3>Simulations Plus's Economic Impact: An Analysis</h3>
Revenue Growth: Simulations Plus displayed positive results in 3 months. As of 31 May, 2024, the company achieved a solid revenue growth rate of approximately 14.23%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Interpreting Earnings Metrics:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 71.49%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Simulations Plus's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 0.16.
</li>
</ul>
Debt Management: Simulations Plus's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: Simulations Plus's current Price to Earnings (P/E) ratio of 71.42 is higher than the industry average, indicating that the stock may be overvalued according to market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 10.4 is above industry norms, reflecting an elevated valuation for Simulations Plus's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio of 39.26, the company's market valuation exceeds industry averages.
</li>
</ul>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Delving Into the Significance of Insider Transactions</h3>
Insider transactions should be considered alongside other factors when making investment decisions, as they can offer important insights.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Deciphering Transaction Codes in Insider Filings</h3>
Surveying the realm of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often give prominence to those unfolding in the open market, systematically detailed in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001023459">Check Out The Full List Of Simulations Plus's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Capitalizing In Growth Prospects, Daniel Szot Acquires In Simulations Plus Stock Options

A noteworthy insider acquisition was disclosed on October 21, as Szot, Chief Revenue Officer at Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>), reported the acquisition of stock options for 7,500 shares.
What Happened: In a recent Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001023459/000102345924000121//Archives/edgar/data/1023459/000102345924000121/0001023459-24-000121-index.htm">U.S. Securities and Exchange Commission</a> on Monday, Szot, Chief Revenue Officer at Simulations Plus, acquired 7,500 stock options for SLP with an exercise price of $33.29 per share.
Currently, Simulations Plus shares are trading down 0.82%, priced at $34.0 during Tuesday's morning. This values Szot's 7,500 shares at $5,325.
<h3>Discovering Simulations Plus: A Closer Look</h3>
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. It generates maximum revenue from the software segment.
<h3>Key Indicators: Simulations Plus's Financial Health</h3>
Revenue Growth: Simulations Plus's revenue growth over a period of 3 months has been noteworthy. As of 31 May, 2024, the company achieved a revenue growth rate of approximately 14.23%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Profitability Metrics:
<ul>
<li>
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 71.49%, indicating potential difficulties in maintaining profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Simulations Plus's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 0.16.
</li>
</ul>
Debt Management: Simulations Plus's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
Valuation Metrics: A Closer Look
<ul>
<li>
Price to Earnings (P/E) Ratio: The current Price to Earnings ratio of 71.42 is higher than the industry average, indicating the stock is priced at a premium level according to the market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 10.4 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Simulations Plus's EV/EBITDA ratio stands at 39.26, surpassing industry benchmarks. This places the company in a position with a higher-than-average market valuation.
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Illuminating the Importance of Insider Transactions</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>A Deep Dive into Insider Transaction Codes</h3>
When dissecting transactions, the focal point for <a href="https://www.benzinga.com/money/investing-tools">investors</a> is often those occurring in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001023459">Check Out The Full List Of Simulations Plus's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Daniel Szot Backs Up Beliefs With A Notable Acquisition In Simulations Plus Stock Options

On October 21, Fiedler-Kelly, Business Unit President at Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>), executed a strategic insider move by acquiring stock options for 7,500 shares.
What Happened: In a recent Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001023459/000102345924000123//Archives/edgar/data/1023459/000102345924000123/0001023459-24-000123-index.htm">U.S. Securities and Exchange Commission</a> on Monday, Fiedler-Kelly, Business Unit President at Simulations Plus, acquired 7,500 stock options for SLP with an exercise price of $33.29 per share.
Currently, Simulations Plus shares are trading down 0.82%, priced at $34.0 during Tuesday's morning. This values Fiedler-Kelly's 7,500 shares at $5,325.
<h3>Delving into Simulations Plus's Background</h3>
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. It generates maximum revenue from the software segment.
<h3>Simulations Plus's Financial Performance</h3>
Revenue Growth: Simulations Plus's revenue growth over a period of 3 months has been noteworthy. As of 31 May, 2024, the company achieved a revenue growth rate of approximately 14.23%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 71.49%, indicating potential difficulties in maintaining profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Simulations Plus's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of 0.16.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.01, Simulations Plus adopts a prudent financial strategy, indicating a balanced approach to debt management.
Analyzing Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: A higher-than-average P/E ratio of 71.42 suggests caution, as the stock may be overvalued in the eyes of investors.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 10.4, Simulations Plus's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Boasting an EV/EBITDA ratio of 39.26, Simulations Plus demonstrates a robust market valuation, outperforming industry benchmarks.
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
While insider transactions provide valuable information, they should be part of a broader analysis in making investment decisions.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Unlocking the Meaning of Transaction Codes</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001023459">Check Out The Full List Of Simulations Plus's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Capitalizing In Growth Prospects, Jill Fiedler-Kelly Acquires In Simulations Plus Stock Options

Disclosed in a recent SEC filing, Jill Fiedler-Kelly, Business Unit President at Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>), made a strategic move by acquiring company stock options on October 21,.
What Happened: Fiedler-Kelly, Business Unit President at Simulations Plus, acquired stock options for 7,500 shares of SLP. This information was disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001023459/000102345924000123//Archives/edgar/data/1023459/000102345924000123/0001023459-24-000123-index.htm">U.S. Securities and Exchange Commission</a> on Monday. The options allow Fiedler-Kelly to buy the company's stock at $33.29 per share.
The Tuesday morning update indicates Simulations Plus shares down by 0.82%, currently priced at $34.0. At this value, Fiedler-Kelly's 7,500 shares are worth $5,325.
<h3>Delving into Simulations Plus's Background</h3>
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. It generates maximum revenue from the software segment.
<h3>Financial Insights: Simulations Plus</h3>
Revenue Growth: Simulations Plus displayed positive results in 3 months. As of 31 May, 2024, the company achieved a solid revenue growth rate of approximately 14.23%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Exploring Profitability:
<ul>
<li>
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 71.49%, indicating potential difficulties in maintaining profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Simulations Plus's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 0.16.
</li>
</ul>
Debt Management: Simulations Plus's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
Exploring Valuation Metrics Landscape:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current Price to Earnings ratio of 71.42 is higher than the industry average, indicating the stock is priced at a premium level according to the market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 10.4 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an impressive EV/EBITDA ratio of 39.26, Simulations Plus demonstrates exemplary market valuation, surpassing industry averages.
</li>
</ul>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
While insider transactions provide valuable information, they should be part of a broader analysis in making investment decisions.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Essential Transaction Codes Unveiled</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001023459">Check Out The Full List Of Simulations Plus's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Strategic Move: Jill Fiedler-Kelly Enhances Portfolio With Simulations Plus Stock Options

On October 21, O'Connor, Chief Executive Officer at Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>), executed a strategic insider move by acquiring stock options for 32,500 shares.
What Happened: In a recent Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001023459/000102345924000127//Archives/edgar/data/1023459/000102345924000127/0001023459-24-000127-index.htm">U.S. Securities and Exchange Commission</a> on Monday, O'Connor, Chief Executive Officer at Simulations Plus, acquired 32,500 stock options for SLP with an exercise price of $33.29 per share.
Simulations Plus shares are currently trading down by 0.0%, with a current price of $34.28 as of Tuesday morning. This brings the total value of O'Connor's 32,500 shares to $32,175.
<h3>Discovering Simulations Plus: A Closer Look</h3>
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. It generates maximum revenue from the software segment.
<h3>A Deep Dive into Simulations Plus's Financials</h3>
Revenue Growth: Over the 3 months period, Simulations Plus showcased positive performance, achieving a revenue growth rate of 14.23% as of 31 May, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Exploring Profitability:
<ul>
<li>
Gross Margin: The company faces challenges with a low gross margin of 71.49%, suggesting potential difficulties in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, Simulations Plus exhibits below-average bottom-line performance with a current EPS of 0.16.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
Analyzing Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: Simulations Plus's stock is currently priced at a premium level, as reflected in the higher-than-average P/E ratio of 71.42.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 10.4 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): A high EV/EBITDA ratio of 39.26 positions the company as being more valued compared to industry benchmarks.
</li>
</ul>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Exploring the Significance of Insider Trading</h3>
Investors should view insider transactions as part of a multifaceted analysis and not rely solely on them for decision-making.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>Transaction Codes Worth Your Attention</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001023459">Check Out The Full List Of Simulations Plus's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Shawn O'Connor Backs Up Beliefs With A Notable Acquisition In Simulations Plus Stock Options

Disclosed in a recent SEC filing, Shawn O'Connor, Chief Executive Officer at Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>), made a strategic move by acquiring company stock options on October 21,.
What Happened: O'Connor, Chief Executive Officer at Simulations Plus, engaged in a derivative transaction according to a Form 4 filing on Monday with the <a href="https://www.sec.gov/Archives/edgar/data/0001023459/000102345924000127//Archives/edgar/data/1023459/000102345924000127/0001023459-24-000127-index.htm">U.S. Securities and Exchange Commission</a>. This involved the acquisition of stock options for 32,500 shares of SLP, providing the right to purchase the company's stock at an exercise price of $33.29 per share.
The Tuesday morning update indicates Simulations Plus shares down by 0.82%, currently priced at $34.0. At this value, O'Connor's 32,500 shares are worth $23,075.
<h3>Get to Know Simulations Plus Better</h3>
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. It generates maximum revenue from the software segment.
<h3>Simulations Plus: A Financial Overview</h3>
Revenue Growth: Over the 3 months period, Simulations Plus showcased positive performance, achieving a revenue growth rate of 14.23% as of 31 May, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Profitability Metrics:
<ul>
<li>
Gross Margin: With a low gross margin of 71.49%, the company exhibits below-average profitability, signaling potential struggles in cost efficiency compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Simulations Plus's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 0.16.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.01, Simulations Plus adopts a prudent financial strategy, indicating a balanced approach to debt management.
Insights into Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a higher-than-average P/E ratio of 71.42, Simulations Plus's stock is perceived as being overvalued in the market.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 10.4 is above industry norms, reflecting an elevated valuation for Simulations Plus's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): A high EV/EBITDA ratio of 39.26 positions the company as being more valued compared to industry benchmarks.
</li>
</ul>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Understanding the Significance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>Navigating the World of Insider Transaction Codes</h3>
Navigating through the landscape of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, precisely detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001023459">Check Out The Full List Of Simulations Plus's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Capitalizing In Growth Prospects, Shawn O'Connor Acquires In Simulations Plus Stock Options

Partnership will advance the field of ligand-based virtual screening to improve drug design and optimization activities
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.simulations-plus.com%2F%3Fmtm_campaign%3DSPL_and_UC_NIH_Grant_to_develop_AI_Drug_Discovery%26mtm_source%3Dissuerdirect%26mtm_medium%3Dpressrelease&amp;esheet=54132470&amp;newsitemid=20241008571649&amp;lan=en-US&amp;anchor=Simulations+Plus%2C+Inc.&amp;index=1&amp;md5=0a081cc4e4c22d01bff5afaf02e19944">Simulations Plus, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the award of a new research grant from the National Institutes of Health (NIH), secured in partnership with the University of Southern California (USC) Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences. The grant will be used to evaluate novel computational methods that account for water-ligand interactions in drug discovery and that integrate with the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.simulations-plus.com%2Fsoftware%2Fadmetpredictor%2Fai-driven-drug-design-aidd%2F%3Fmtm_campaign%3DSPL_and_UC_NIH_Grant_to_develop_AI_Drug_Discovery%26mtm_source%3Dissuerdirect%26mtm_medium%3Dpressrelease&amp;esheet=54132470&amp;newsitemid=20241008571649&amp;lan=en-US&amp;anchor=Artificial+Intelligence-driven+Drug+Design&amp;index=2&amp;md5=85c5f141d5882c723c264d7f10f3c8ab">Artificial Intelligence-driven Drug Design</a> (AIDD) module in <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.simulations-plus.com%2Fsoftware%2Fadmetpredictor%2F%3Fmtm_campaign%3DSPL_and_UC_NIH_Grant_to_develop_AI_Drug_Discovery%26mtm_source%3Dissuerdirect%26mtm_medium%3Dpressrelease&amp;esheet=54132470&amp;newsitemid=20241008571649&amp;lan=en-US&amp;anchor=ADMET+Predictor%26%23174%3B&amp;index=3&amp;md5=a883274edf2b91a49666979402e4c3ff">ADMET Predictor&#xAE;</a> to offer a first-of-its-kind ligand-based virtual screening (LBVS) solution for pharmaceutical companies.

Contracts

Simulations Plus And The University Of Southern California Secure NIH Grant To Develop New AI Drug Discovery Offerings

Providing a diverse range of perspectives from bullish to bearish, 2 analysts have published ratings on Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Simulations Plus, presenting an average target of $51.5, a high estimate of $56.00, and a low estimate of $47.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 8.04%. 
<img src="https://www.benzinga.com/files/images/story/2024/1726142430_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Simulations Plus. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Schoenhaus</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$47.00</td>
<td>-</td>
</tr>
<tr>
<td>Matt Hewitt</td>
<td>Craig-Hallum</td>
<td>Maintains</td>
<td>Buy</td>
<td>$56.00</td>
<td>$56.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Simulations Plus. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Simulations Plus compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Simulations Plus's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Simulations Plus's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SLP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Simulations Plus analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Simulations Plus Better</h2>
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. It generates maximum revenue from the software segment.
<h3>Simulations Plus: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Simulations Plus showcased positive performance, achieving a revenue growth rate of 14.23% as of 31 May, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Simulations Plus's net margin is impressive, surpassing industry averages. With a net margin of 16.92%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Simulations Plus's ROE excels beyond industry benchmarks, reaching 1.75%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.62%, the company showcases effective utilization of assets.
Debt Management: Simulations Plus's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Simulations Plus: 2 Analysts Share Their Views

Simulations Plus Non-GAAP EPS of $0.06 in-line, revenue of $18.7M misses by $1.03M

Reports Q4 revenue $18.7M, consensus $19.74M. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news....

Simulations Plus reports Q4 adjusted EPS 6c, consensus 3c

Sees FY25 revenue $90M-$93M, consensus $91.75M. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial new...

Simulations Plus sees FY25 adjusted EPS $1.07-$1.20, consensus 63c

Simulations Plus, Inc. (SLP) Q4 2024 Earnings Call Transcript

In a report released today, Constantine Davides from JMP Securities maintained a Hold rating on Simulations Plus (SLP – Research Report). The compa...

JMP Securities Reaffirms Their Hold Rating on Simulations Plus (SLP)

Conestoga Capital Advisors Q3 2024 Quarterly Commentary

Simulations Plus (SLP) announced a newly funded grant from the U.S. Food and Drug Administration FDA , secured in partnership with the University o...

FDA awards grant to validate in vitro-in vivo extrapolation to Simulations Plus

Simulations Plus (SLP) has disclosed a new risk, in the Accounting & Financial Operations category. Simulations Plus has made a strategic decision ...

Simulations Plus Halts Dividends to Boost Long-Term Growth: What It Means for Investors

Simulations Plus (SLP) announced that it has been awarded a newly funded grant from the U.S. Food and Drug Administration FDA to use physiologicall...

FDA grants Simulations Plus to use PBPK to expand mechanistic modeling for LAI

Stephens analyst Jeff Garro initiated coverage of Simulations Plus (SLP) with an Overweight rating and $39 price target Simulations Plus addresses ...

Simulations Plus initiated with an Overweight at Stephens

AAON

ALTR

ANSS

AXON

BLFS

BWMN

CGNX

COCO

CPRT

CSGP

CSWI

CWST

DSGX

ERII

EXPO

FIVN

FOXF

FTNT

GWRE

HLMN

IDXX

IRMD

MAMA

MNESP

NOVT

OFLX

PCOR

PLMR

POOL

QTWO

RGEN

ROAD

SITE

SNPS

SPSC

TCYSF

TECH

THBRF

TKNO

TREX

TRNS

USPH

VCEL

VRSK

WLDN

Press Releases

Simulations Plus Releases DILIsym® X

Simulations Plus Optimizes Business Unit Structure to Support Future Growth Following Recent Strategic Acquisitions

Simulations Plus to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Simulations Plus and the University of Southern California Secure NIH Grant to Develop New AI Drug Discovery Offerings

Simulations Plus Announces Fourth Quarter and Fiscal Year 2024 Earnings and Conference Call Date

Simulations Plus Reports Fourth Quarter and Fiscal 2024 Financial Results

Simulations Plus and Partners Awarded New FDA Grant to Validate In Vitro-In Vivo Extrapolation Methods for Complex Formulations

Simulations Plus to Participate in the Stephens Annual Investment Conference

Simulations Plus and the University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables

Simulations Plus to Participate in the BTIG Digital Health Forum

Firefly Neuroscience, Inc. - Common Stock

Firefly Neuroscience

American Well Corporation Class A Common Stock

American Well

CareCloud

Certara

Definitive Healthcare Corp. - Class A Common Stock

Definitive Healthcare

Doximity

DarioHealth

Evolent Health

Forian

GoodRx Holdings, Inc. - Class A Common Stock

GoodRx Holdings

Health Catalyst

HealthStream

icad

LifeMD

MultiPlan Corporation Class A Common Stock

MultiPlan

OptimizeRx

Phreesia

Pheton Holdings Ltd - Class A Ordinary Shares

Pheton Holdings

Scienture Holdings

Schrodinger

Sophia Genetics

TruBridge

Teladoc Health

Veeva Systems

Waystar Holding

Stephens & Co.

BTIG

Keybanc

Craig-Hallum

Oppenheimer

주식선물이 오늘 목요일 아침 미국에서 상승하면서, 오늘 투자자들의 주목을 끌 수 있는 몇 가지 주식은 다음과 같다.
월스트리트는 콘아그라 브랜즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>)의 개장 전에 1주당 65센트의 분기 실적과 301억달러의 매출을 발표할 것으로 예상하고 있다. 이는 <a href="https://pro.benzinga.com/dashboard">벤징가 프로</a>의 데이터에 따른 것이다. 콘아그라 주식은 시간외 거래에서 0.5% 상승하여 29.06달러에 거래되었다.
리바이 스트라우스(리바이스) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>)는 첫 분기에 대한 기쁜 소식을 보고하고 2024년 이익에 대한 지침을 강화했다.
분석가들은 RPM 인터내셔널(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>)이 152억 달러의 매출과 함께 주당 46센트를 벌어들였을 것으로 예상하고 있다. 이 기업은 시장 오픈 전에 이익을 발표할 예정이다.
여기에서 <a href="https://www.benzinga.com/premarket/"> 사전장 개요를 확인하세요 </a> 
시뮬레이션즈 플러스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>)는 2분기의 예상을 초과하는 실적을 발표했다. 이 회사는 또한 6600만 ~ 6900만 달러의 매출과 주당 66센트에서 68센트의 24년도 이익을 예상한다고 밝혔다. 주가는 시간외 거래에서 8.92% 상승한 41.89달러를 기록했다.
분석가들은 램 웨스턴 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>)가 개장 전에 주당 1.45달러의 분기 실적과 165억 달러의 매출을 발표할 것으로 예상한다. 램 웨스턴 주식은 시간외 거래에 0.87% 상승하여 102달러에 거래되었다.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38067894/calcimedica-and-2-other-penny-stocks-insiders-are-buying">CalciMedica의다른 투자자들이 사는 페니 주식 2종-</a>

Comments

Simulations Plus

뉴스

에 대한 최신 뉴스 Simulations Plus (NASDAQ:SLP) 주식

목요일, 4월 04, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌